Summary sheet
The project finances the borrower's expenditures over the next three years related to Masitinib and its analogues against COVID-19 (non-clinical and clinical studies, drug manufacturing including stock piling, related regulatory expenses, related general and administrative (G&A) expenses).The project will be implemented from Paris, France.
The project finances the borrower's expenditures over the next three years related to Masitinib and its analogues against COVID-19 (non-clinical and clinical studies, drug manufacturing including stock piling, related regulatory expenses, related G&A expenses).The project will be implemented from Paris, France. The company's innovative approach might prevent complications linked to severe pulmonary inflammation and thrombotic events potentially leading to death. It also aims to reduce the burden on intensive care units and more invasive treatment options. By co-investing in the project, the Bank contributes to improving healthcare, whilst also fostering the generation of European scientific knowledge and acumen, preserving and cultivating highly skilled employment opportunities.
The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The Promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. Details will be assessed during the project's due diligence.